Yano T, Tanaka F, Ouchi K, Kawahara M, Fujino K, Shima R, Rikimaru T, Ichikawa Y, Oizumi K
Department of Medicine, Kurume University School of Medicine, Japan.
Kurume Med J. 1993;40(4):213-8. doi: 10.2739/kurumemedj.40.213.
The efficacy and safety of oral ofloxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied. The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S. pneumoniae), Staphylococcus aureus (S. aureus), Gram positive cocci unidentified, Pseudomonas aeruginosa (P. aeruginosa), Morexella catarrhalis, Streptococcus epidermidis, and another Haemophilus species in this order. All these bacteria were susceptible to ofloxacin except for one strain of methicillin resistant S. aureus. A satisfactory clinical outcome was achieved in 34 of 40 patients (85%). It is concluded that ofloxacin, 400 mg once daily, is useful for patients with respiratory tract infections.
对每日一次口服400毫克氧氟沙星治疗下呼吸道感染患者的疗效和安全性进行了研究。从这些患者痰液标本中分离出的最常见菌种依次为流感嗜血杆菌、肺炎链球菌、金黄色葡萄球菌、未鉴定的革兰氏阳性球菌、铜绿假单胞菌、卡他莫拉菌、表皮葡萄球菌和另一种嗜血杆菌。除一株耐甲氧西林金黄色葡萄球菌外，所有这些细菌对氧氟沙星均敏感。40例患者中有34例（85%）取得了满意的临床疗效。结论是，每日一次口服400毫克氧氟沙星对呼吸道感染患者有效。
